CD20 antibodies: Type II to tango?

Blood

Volumn 119, Issue 22, 2012, Pages 5061-5063

  Van Oers, Marinus H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD20 ANTIGEN; CHLORAMBUCIL; OBINUTUZUMAB; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

EID: 84861833979     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-420711     Document Type: Note

References (8)

1. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti- CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126-5132.
2. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118-5125.
3. Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
4. Alduaij W, Ivanov A, Honeychurch J, et al. Novel type 2 anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519- 4529.
5. Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type 1/2 distinction of CD20 antibodies. Blood. 2011;118(2):358-367.
6. Salles GA, Morschhauser F, Thieblemont C, et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma: results from a phase 1/2 study (BO20999). Blood (ASH Annual Meeting Abstracts). 2011;118:268.
7. Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood. 2012;119(16): 3698-3704.
8. Sehn LH, Goy A, Offner FC, et al. Randomized phase 2 trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20 indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS Study. Blood (ASH Annual Meeting Abstracts). 2011;118:269.